A H3K27M-targeted vaccine in adults with diffuse midline glioma.

Humans Adult Animals Mice Brain Neoplasms / genetics Histones / genetics Glioma / genetics Mutation / genetics Vaccines

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
10 2023

Historique:

received: 23 02 2023

accepted: 22 08 2023

medline: 23 10 2023

pubmed: 22 9 2023

entrez: 22 9 2023

Statut: ppublish

Résumé

Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M

Identifiants

DOI: 10.1038/s41591-023-02555-6 PMID: 37735561 PMC: PMC10579055

pubmed: 37735561

doi: 10.1038/s41591-023-02555-6

pii: 10.1038/s41591-023-02555-6

pmc: PMC10579055

doi:

Substances chimiques

Histones 0

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

2586-2592

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231–1251 (2021).

doi: 10.1093/neuonc/noab106 pubmed: 34185076 pmcid: 8328013

Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660–672 (2013).

doi: 10.1016/j.ccr.2013.10.006 pubmed: 24183680

Jessa, S. et al. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat. Genet. 54, 1865–1880 (2022).

doi: 10.1038/s41588-022-01205-w pubmed: 36471070 pmcid: 9742294

Liu, I. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat. Genet. 54, 1881–1894 (2022).

doi: 10.1038/s41588-022-01236-3 pubmed: 36471067 pmcid: 9729116

Kramm, C. M. et al. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro. Oncol. 13, 680–689 (2011).

doi: 10.1093/neuonc/nor045 pubmed: 21636712 pmcid: 3107103

Robison, N. J. & Kieran, M. W. Diffuse intrinsic pontine glioma: a reassessment. J. Neurooncol. 119, 7–15 (2014).

doi: 10.1007/s11060-014-1448-8 pubmed: 24792486

Vuong, H. G., Ngo, T. N. M., Le, H. T. & Dunn, I. F. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. J. Neurooncol. 158, 405–412 (2022).

doi: 10.1007/s11060-022-04027-2 pubmed: 35606633

Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro. Oncol. 20, 674–686 (2018).

doi: 10.1093/neuonc/nox208 pubmed: 29106665

Vinci, M. et al. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nat. Med. 24, 1204–1215 (2018).

doi: 10.1038/s41591-018-0086-7 pubmed: 29967352 pmcid: 6086334

Jha, P. et al. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology 39, 413–424 (2019).

doi: 10.1111/neup.12594 pubmed: 31625205

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

doi: 10.1038/nature12477 pubmed: 23945592 pmcid: 3776390

McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).

doi: 10.1126/science.aaf1490 pubmed: 26940869 pmcid: 4984254

Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517–523 (2020).

doi: 10.1038/s41586-020-2209-9 pubmed: 32322066 pmcid: 8235024

Cacciotti, C. et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J. Neurooncol. 149, 113–122 (2020).

doi: 10.1007/s11060-020-03578-6 pubmed: 32627129

Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).

doi: 10.1038/s41586-022-04489-4 pubmed: 35130560 pmcid: 8967714

Martínez-Vélez, N. et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat. Commun. 10, 2235 (2019).

doi: 10.1038/s41467-019-10043-0 pubmed: 31138805 pmcid: 6538754

Mueller, S. et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J. Clin. Invest. 130, 6325–6337 (2020).

doi: 10.1172/JCI140378 pubmed: 32817593 pmcid: 7685729

Ochs, K. et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology 6, e1328340 (2017).

doi: 10.1080/2162402X.2017.1328340 pubmed: 28811969 pmcid: 5543817

Immisch, L. et al. H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2

Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463–468 (2021).

doi: 10.1038/s41586-021-03363-z pubmed: 33762734 pmcid: 8046668

Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327 (2014).

doi: 10.1038/nature13387 pubmed: 25043048

Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235–251 (2023).

doi: 10.1016/j.ccell.2022.12.007 pubmed: 36638785

Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192–1203 (2018).

doi: 10.1038/s41591-018-0095-6 pubmed: 29988124

Reardon, D. A. et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin. Cancer Res. 26, 1586–1594 (2020).

doi: 10.1158/1078-0432.CCR-18-1140 pubmed: 32034072

Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

doi: 10.1016/S1470-2045(17)30517-X pubmed: 28844499

Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126–135 (2019).

doi: 10.1097/CJI.0000000000000260 pubmed: 30882547 pmcid: 6691897

van den Bent, M. J. et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro. Oncol. 17, 935–941 (2015).

doi: 10.1093/neuonc/nov013 pubmed: 25691693 pmcid: 5762005

Bunse, L. et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J. Clin. Invest. 125, 593–606 (2015).

pubmed: 25555220 pmcid: 4319432

Grant, C. E. & Bailey, T. L. XSTREME: comprehensive motif analysis of biological sequence datasets. Preprint at bioRxiv https://doi.org/10.1101/2021.09.02.458722 (2021).